Suprabasin enhances the invasion, migration, and angiogenic ability of oral squamous cell carcinoma cells under hypoxic conditions.
Humans
Animals
Mice
Carcinoma, Squamous Cell
/ pathology
Mouth Neoplasms
/ pathology
Vascular Endothelial Growth Factor A
/ genetics
Squamous Cell Carcinoma of Head and Neck
/ genetics
Caspase 3
Bromodeoxyuridine
Cell Proliferation
/ genetics
Vascular Endothelial Growth Factors
Cell Movement
Head and Neck Neoplasms
Hypoxia
/ genetics
Cell Line, Tumor
Antigens, Differentiation
/ genetics
Neoplasm Proteins
angiogenesis
cell invasion
cell proliferation
hypoxia
oral cancers
squamous cell carcinoma
suprabasin
Journal
Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
14
09
2022
accepted:
09
01
2023
entrez:
10
3
2023
pubmed:
11
3
2023
medline:
14
3
2023
Statut:
ppublish
Résumé
Suprabasin (SBSN) is a secreted protein that is isolated as a novel gene expressed in differentiated keratinocytes in mice and humans. It induces various cellular processes such as proliferation, invasion, metastasis, migration, angiogenesis, apoptosis, therapy and immune resistance. The role of SBSN was investigated in oral squamous cell carcinoma (OSCC) under hypoxic conditions using the SAS, HSC‑3, and HSC‑4 cell lines. Hypoxia induced SBSN mRNA and protein expression in OSCC cells and normal human epidermal keratinocytes (NHEKs), and this was most prominent in SAS cells. The function of SBSN in SAS cells was analyzed using 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide (MTT); 5‑bromo‑2'‑deoxyuridine (BrdU); cell cycle, caspase 3/7, invasion, migration, and tube formation assays; and gelatin zymography. Overexpression of SBSN decreased MTT activity, but the results of BrdU and cell cycle assays indicated upregulation of cell proliferation. Western blot analysis for cyclin‑related proteins indicated involvement of cyclin pathways. However, SBSN did not strongly suppress apoptosis and autophagy, as revealed by caspase 3/7 assay and western blotting for p62 and LC3. Additionally, SBSN increased cell invasion more under hypoxia than under normoxia, and this resulted from increased cell migration, not from matrix metalloprotease activity or epithelial‑mesenchymal transition. Furthermore, SBSN induced angiogenesis more strongly under hypoxia than under normoxia. Analysis using reverse transcription‑quantitative PCR showed that vascular endothelial growth factor (VEGF) mRNA was not altered by the knockdown or overexpression of SBSN VEGF, suggesting that VEGF is not located downstream of SBSN. These results demonstrated the importance of SBSN in the maintenance of survival and proliferation, invasion and angiogenesis of OSCC cells under hypoxia.
Identifiants
pubmed: 36896786
doi: 10.3892/or.2023.8520
pii: 83
pmc: PMC10035061
doi:
pii:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Caspase 3
EC 3.4.22.-
Bromodeoxyuridine
G34N38R2N1
Vascular Endothelial Growth Factors
0
SBSN protein, human
0
Antigens, Differentiation
0
Neoplasm Proteins
0
suprabasin protein, mouse
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Anal Cell Pathol (Amst). 2019 Nov 26;2019:9423907
pubmed: 31886121
PLoS One. 2009 Dec 04;4(12):e8189
pubmed: 19997593
Int J Clin Oncol. 2016 Oct;21(5):883-889
pubmed: 27000845
Cell Metab. 2021 Jul 6;33(7):1307-1321
pubmed: 33915111
Eur Rev Med Pharmacol Sci. 2018 Aug;22(16):5071-5076
pubmed: 30178824
J Surg Oncol. 2006 Mar 15;93(4):330-7
pubmed: 16496371
Nat Cell Biol. 2016 Apr;18(4):356-65
pubmed: 27027486
J Natl Cancer Inst. 2001 Feb 21;93(4):266-76
pubmed: 11181773
Trends Pharmacol Sci. 2012 Apr;33(4):207-14
pubmed: 22398146
Cell Biosci. 2021 Jul 3;11(1):122
pubmed: 34217360
Mol Oncol. 2019 Jul;13(7):1467-1489
pubmed: 30919591
Mol Oncol. 2020 Oct;14(10):2403-2419
pubmed: 32696549
Carcinogenesis. 2020 Nov 13;41(11):1543-1552
pubmed: 32055838
J Immunol. 2020 Jul 1;205(1):282-289
pubmed: 32471882
Biology (Basel). 2021 Aug 08;10(8):
pubmed: 34439992
Genes Dev. 2016 Sep 1;30(17):1913-30
pubmed: 27664235
Tumour Biol. 2017 Apr;39(4):1010428317695527
pubmed: 28381176
Int J Oncol. 2017 May;50(5):1634-1646
pubmed: 28339026
Cancer Res. 1999 Nov 15;59(22):5830-5
pubmed: 10582706
Cancer Sci. 2014 Dec;105(12):1533-40
pubmed: 25283635
Medicina (Kaunas). 2019 Dec 30;56(1):
pubmed: 31906017
Cells Tissues Organs. 2021;210(5-6):326-338
pubmed: 34412050
Rom J Morphol Embryol. 2018;59(2):455-467
pubmed: 30173249
PLoS One. 2012;7(11):e48582
pubmed: 23144906
Genes (Basel). 2021 Jan 18;12(1):
pubmed: 33477529
Anticancer Res. 2021 Dec;41(12):6077-6086
pubmed: 34848462
Int J Mol Sci. 2018 Aug 16;19(8):
pubmed: 30115834
J Oral Pathol Med. 1989 Aug;18(7):391-5
pubmed: 2585303
Int J Mol Sci. 2020 Jul 02;21(13):
pubmed: 32630820
Sci Rep. 2016 Feb 22;6:21549
pubmed: 26899563
Mol Cancer. 2015 Feb 21;14:48
pubmed: 25743109
Cancer Res. 2009 Apr 15;69(8):3713-20
pubmed: 19351860
Clin Cancer Res. 2000 Mar;6(3):1161-8
pubmed: 10741747
Mol Cancer. 2019 Nov 11;18(1):157
pubmed: 31711497
J Biol Chem. 2002 Nov 22;277(47):45195-202
pubmed: 12228223
Sci Rep. 2020 Sep 3;10(1):14559
pubmed: 32884021
J Cell Biol. 2020 Jan 6;219(1):
pubmed: 31753861
Mol Biol Rep. 2022 Feb;49(2):1453-1461
pubmed: 34775572
J Cell Biol. 2005 Nov 21;171(4):603-14
pubmed: 16286508
J Proteome Res. 2011 Jul 1;10(7):3149-59
pubmed: 21574646
Mol Cancer. 2020 Jan 22;19(1):12
pubmed: 31969156
Nat Rev Cancer. 2013 Feb;13(2):97-110
pubmed: 23344542
Cell Oncol (Dordr). 2013 Jun;36(3):233-45
pubmed: 23529586
Nat Rev Cancer. 2011 Jun;11(6):393-410
pubmed: 21606941
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Cancers (Basel). 2021 Jun 17;13(12):
pubmed: 34204259
Biomed Res Int. 2015;2015:549412
pubmed: 26146622
Pharmacol Ther. 2016 Aug;164:152-69
pubmed: 27139518
Gynecol Oncol. 2003 May;89(2):325-33
pubmed: 12713999
EMBO J. 2000 Nov 1;19(21):5720-8
pubmed: 11060023
Cell Biosci. 2015 Mar 28;5:14
pubmed: 25844158
J Dermatol Sci. 2019 Sep;95(3):107-112
pubmed: 31399284
Oral Maxillofac Surg. 2012 Jun;16(2):189-96
pubmed: 22592457